以硼替佐米为主的三药化疗方案治疗多发性骨髓瘤的疗效及不良反应观察

Observation of curative effect and adverse reaction of three-agent bortezomib-based chemotherapy for multiple myeloma

目的探究以硼替佐米为主的三药化疗方案治疗多发性骨髓瘤(MM)的疗效及不良反应。方法选取2018年5月至2020年5月本院收治的94例MM初诊患者作为研究对象,依据随机数字表法分为两组,各47例。对照组给予传统化疗方案治疗,观察组给予以硼替佐米为主的三药化疗方案治疗,比较两组临床疗效、骨代谢指标及不良反应发生情况。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05);治疗后,观察组血清碱性磷酸酶(ALP)、血清骨钙素(BGP)水平均高于对照组,Ⅰ型胶原C末端肽(CTX-Ⅰ)低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较差异无统计学意义。结论以硼替佐米为主的三药化疗方案治疗MM的疗效显著,可调节骨代谢指标,且未增加不良反应,安全性较高。

Objective To explore the efficacy and adverse reactions of three-drug bortezomib-based chemotherapy for multiple myeloma(MM).Methods 94 newly diagnosed patients with MM admitted to our hospital from May 2018 to May 2020 were selected as the research subjects,and they were divided into two groups according to the random number table method,with 47 cases in each group.The control group was given traditional chemotherapy,and the observation group was given three-agent bortezomib-based chemotherapy,the efficacy,bone metabolism indexes and adverse reactions were compared between the two groups.Results The total clinical effective rate in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05);after treatment,the alkaline phosphatase(ALP)and bone gammacarboxyglutamic acid-containing protein(BGP)in the observation group were higher than those in the control group,and the C-terminal cross linked peptide-Ⅰ(CTX-Ⅰ)in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Three-drug bortezomib-based chemotherapy regimen has significant curative effect in the treatment of MM can promote the regulation of bone metabolism indexes,and does not increase adverse reactions,with high safety.